Ascorbic acid 500mg/2ml / Nicotinamide 160mg/2ml solution for injection ampoules
Requires a prescription from a doctor or prescriber
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Ascorbic acid + Nicotinamide
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
MHRA licensed products
View all licensed products for Ascorbic acid + Nicotinamide on the MHRA register
Pabrinex Intramuscular High Potency No.2 solution for injection 2ml ampoules
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 12 · Randomised trials: 6 · 1956–2026
Showing the 50 most relevant studies, sorted by most relevant.
Oludemi Taofiq, Ana M. Gonzaléz‐Paramás, Maria Filomena Barreiro, et al.
Molecules, 2017
- Cosmeceuticals
- Administration, Topical
- Anti-Infective Agents
Xin Yin, Kaiwen Chen, Hao Cheng, et al.
Antioxidants, 2022
Muhammad Nadeem, Muhammad Imran, Tanweer Aslam Gondal, et al.
Applied Sciences, 2019
Ebrahimirad F, Mirmahdizade SE, Mahmoodieh B, et al.
2025
BackgroundCellular senescence, characterized by irreversible cell cycle arrest, plays a pivotal role in ageing and the development of age-related pathologies. Mitigating oxidative stress, a primary contributor to cellular ageing, is crucial for inhibiting the senescence-associated secretory phenotype (SASP). A comparative analysis of synthetic and natural antioxidants is necessary to evaluate the efficacy of synthetic and natural antioxidants in this context.MethodA systematic review encompassed studies published up to July 2023, utilizing prominent databases such as PubMed, Google Scholar, Scopus, and Web of Science. To enhance the efficiency of data screening and selection, we employed Rayyan. ai, an advanced tool designed for systematic reviews.ResultThe review encompassed 33 studies examining the impact of diverse antioxidants on cellular senescence. Findings indicated that synthetic antioxidants, such as N-acetylcysteine, and natural alternatives, like Vitamin C, demonstrated efficacy in attenuating oxidative stress and senescence markers. Notably, natural antioxidants frequently exhibited comparable or superior efficacy to their synthetic counterparts in most studies. Furthermore, the synergistic effects of antioxidant combinations sometimes yield enhanced benefits. It is worth noting that certain recently developed synthetic compounds, such as MHY2233, have shown promising results, exhibiting greater potency than established antioxidants in mitigating senescence markers.ConclusionDietary practices and the aging process can influence these intricate processes and how they interact, serving as potential primary and secondary preventative strategies. The Mediterranean diet, dietary antioxidants, and limiting calorie intake are promising nutritional strategies. Better insight into the molecular mechanisms of aging may facilitate the development of efficient biomarkers and antioxidants for diagnosis or treatment.Systematic review registrationhttps://osf.io/b67wm/.
Abstract licence: CC BY
Sarkar R, Sahu A
2025
Melasma is a common skin disorder characterized by facial hyperpigmentation, often aggravated by sun exposure. Antioxidants are being studied as a treatment option for their potential to reduce oxidative stress and improve skin pigmentation. A comprehensive literature search was conducted in PubMed for articles published over the past decade, up to January 31, 2024, on the use of antioxidants in melasma treatment. The systematic review, conducted by two independent investigators, included 30 studies on antioxidants in melasma, covering vitamin C, cysteamine, silymarin, PLE, tomato extract/lycopene, zinc sulfate, melatonin, and other antioxidants. Findings indicated that combining vitamin C with physical therapies, such as peels and lasers, yielded better results. Cysteamine, a naturally occurring aminothiol, showed efficacy comparable to hydroquinone with fewer side effects. Silymarin was effective in reducing melasma severity with minimal adverse effects. PLE showed mixed results but potential as an effective antioxidant when combined with other treatments. Lycopene from tomato extract demonstrated significant improvements in melasma when used as an adjuvant therapy. Zinc sulfate showed some effectiveness but was less potent than hydroquinone. Melatonin had antioxidant capabilities but showed no statistically significant improvement. Glutathione is emerging as a new antioxidant therapy showing efficacy in melasma in combination with other topicals and microneedling. Other antioxidants, including combinations of vitamins C, E, and ferulic acid, showed potential as adjuncts in melasma treatment. These findings highlight the diverse efficacy of antioxidants in managing melasma, suggesting their potential as safe and effective treatments.
Abstract licence: CC BY-NC-SA
Mikael Knip, I. F. Douek, W. Moore, et al.
Diabetologia, 2000
- Abnormalities, Drug-Induced
- Diabetes Mellitus, Type 1
- Growth Disorders
Ari Moskowitz, Lars W. Andersen, David T. Huang, et al.
Critical Care, 2018
- Adrenal Cortex Hormones
- Anti-Bacterial Agents
- Ascorbic Acid
Nudrat Aisha Akram, Fahad Shafiq, Muhammad Ashraf
Frontiers in Plant Science, 2017
S. Padayatty, Mark N. Levine
Oral Diseases, 2016
- Ascorbic Acid
- Oral Health
- Recommended Dietary Allowances
Kaio Murilo Monteiro Espíndola, Roseane Guimarães Ferreira, Luis Eduardo Mosquera Narvaez, et al.
Frontiers in Oncology, 2019
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.